KEY INFORMATION

Salary: Dependent on relevant Postdoctoral experience. Future progression is based on annual performance review.
This role is eligible for ICR Sponsorship. Support will be provided for costs associated with Visa application. If you are considering relocating to the UK, further information can be found here.
Duration of Contract: Fixed Term for 3 years
Hours per week: 35 hours per week
Closing Date: 6th April 2025

JOB DETAILS

Professor Johann de Bono’s translational research team is seeking a talented Postdoctoral Training Fellow. The programme focuses on integrating multi-omic and clinical data, including single cell and spatial data as well as hyperplex immunocytochemical data, to help develop novel therapeutic strategies against cancer.
For general information on Post Doc’s at The ICR can be found here.

KEY REQUIREMENTS

The successful candidate will be highly motivated and possess robust bioinformatic, scientific, and analytical skills, with a proactive approach to learning and applying new techniques, including artificial intelligence. Primary responsibilities will involve working with integrated datasets including clinical trial datasets comprising next-generation sequencing data and other applications relevant to the analysis of DNA and RNA sequencing, as well as protein assays. Familiarity with cancer genomics is desirable.
The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 10 years
Department/Directorate Information:
Professor Johann de Bono is a world leader in anticancer drug development, biomarker studies, and prostate cancer care. His team conducts biomarker-driven clinical and translational research to accelerate the development of novel cancer therapies and improve understanding of cancer biology, drug sensitivity and resistance. His team has driven major advances in cancer care through early and late stage trials, and he has led pivotal phase III trials of several prostate cancer drugs including abiraterone, cabazitaxel, enzalutamide, lutetium PSMA and olaparib. His team consists of basic, translational and clinical scientists, and is embedded in a vibrant world-class research environment.
We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Dr Wei Yuan via email on wei.yuan@icr.ac.uk
Due to the high volumes of applications that we receive, we reserve the right to close the advert before the published closing date, once we have received a sufficient number of applications. Therefore, we advise that you to submit your application, as early as possible to avoid disappointment.